Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma.

ABSTRACT:

Abstract

Hematologic toxicity is a common side effect of chimeric antigen receptor T-cell (CAR-T) therapies, being particularly severe among patients with relapsed or refractory multiple myeloma (MM). In this study, we characterized 48 patients treated with B-cell maturation antigen (BCMA) CAR-T cells to understand kinetics of cytopenia, identify predictive factors, and determine potential mechanisms underlying these toxicities. We observed that overall incidence of cytopenia was 95.7%, and grade >3 thrombocytopenia and neutropenia, 1 month after infusion, was observed in 57% and 53% of the patients, respectively, being still present after 1 year in 4 and 3 patients, respectively. Baseline cytopenia and high peak inflammatory markers were highly correlated with cytopenia that persi

SUBMITTER: Palacios-Berraquero ML 

PROVIDER: S-EPMC11532743 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature